GO:1905574 ganglioside GM2 binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905574 (ganglioside GM2 binding) is a molecular_function term defined as binding to ganglioside GM2, a sialylated glycosphingolipid.
• Ganglioside GM2 binding is mediated by proteins such as monoclonal antibody DMAb-1, vimentin, calmodulin, CD1d, CD33-related siglecs, and muscle ganglioside-binding proteins [1,2,4,6,7,8].
• The interaction of GM2 with vimentin intermediate filaments is altered in Tay-Sachs disease fibroblasts, linking the term to lysosomal storage disorders.
• GM2 binding to the calmodulin-binding domain of erythrocyte Ca2+-ATPase modulates enzyme activity, indicating a regulatory role for this interaction.
• In Tay-Sachs disease neurons, activation of ABCC1 transporter ameliorates synaptic dysregulation, highlighting therapeutic relevance of GM2-related pathways.
• GM2 inhibits iNKT cell responses in a CD1d-dependent manner, connecting ganglioside GM2 binding to immune regulation.
Description
Ganglioside GM2 binding (GO:1905574) is a molecular function defined as the selective interaction of a protein or biomolecule with ganglioside GM2, a sialic acid-containing glycosphingolipid that is abundant in the nervous system. This binding event is central to diverse biological processes, including lysosomal lipid metabolism, cytoskeletal organization, immune recognition, and signal transduction [2,4,6]. Researchers study ganglioside GM2 binding to understand how GM2 and its binding partners contribute to normal physiology and to diseases such as Tay-Sachs disease, Parkinson's disease, and immune disorders [2,3,5,6]. The term is also relevant for characterizing antibodies and lectins that recognize GM2, which are valuable tools in diagnostics and therapeutics [1,7]. Because GM2 is a key component of cell membranes, its binding proteins often act as sensors or effectors that translate lipid signals into cellular responses [4,8]. Thus, GO:1905574 provides a framework for annotating gene products that directly interact with GM2, facilitating functional genomics and drug discovery [1,2,4,6,7,8].
ganglioside GM2 binding At A Glance
| GO ID | GO:1905574 |
|---|---|
| GO term | ganglioside GM2 binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to ganglioside GM2, a sialylated glycosphingolipid |
| Definition source | QuickGO |
| Related diseases | Tay-Sachs disease, Parkinson's disease, immune dysregulation |
| Experimental methods | ELISA, surface plasmon resonance, co-immunoprecipitation, CRISPR screens |
What Is GO:1905574?
GO:1905574, ganglioside GM2 binding, is a molecular function term that describes the binding to ganglioside GM2. In other words, it refers to the non-covalent interaction between a protein or other molecule and the GM2 ganglioside, a glycosphingolipid with a terminal N-acetylgalactosamine and sialic acid residue. This binding can occur at the cell surface, within intracellular membranes, or in the cytosol, and it may have structural, signaling, or transport-related consequences [2,4,6].
Why Is ganglioside GM2 binding Important in Cell Biology?
Ganglioside GM2 binding is important because GM2 is a major membrane lipid in the nervous system, and its interactions with proteins influence neuronal development, synaptic function, and immune responses [3,5,6]. Dysregulation of GM2 binding is implicated in lysosomal storage disorders such as Tay-Sachs disease, where GM2 accumulates and alters cytoskeletal and membrane protein interactions [2,5]. Additionally, GM2 binding to immune receptors like CD1d modulates natural killer T cell activation, linking this molecular function to immune surveillance and autoimmunity. Understanding GM2 binding also aids in the development of therapeutic antibodies and small molecules that target GM2-positive cells, such as in cancer immunotherapy [1,7].
• Provides a molecular explanation for GM2-mediated signaling in neurons.
• Links GM2 to cytoskeletal regulation through vimentin binding.
• Modulates ion pump activity via calmodulin-binding domain interactions.
• Influences immune responses by regulating iNKT cell activation through CD1d.
• Serves as a target for monoclonal antibody DMAb-1 in diagnostics.
• Involved in Tay-Sachs disease pathology and potential therapies [2,5].
• Relevant to Parkinson's disease through ganglioside-alpha-synuclein interactions.
• Enables study of CD33-related siglec binding specificity.
• Highlights muscle physiology via ganglioside-binding proteins.
• Facilitates development of GM2-based cancer immunotherapies [1,6].
Molecular Mechanism of ganglioside GM2 binding
Recognition and Binding of GM2 by Proteins
In simple terms: Proteins stick to GM2 on cell membranes.
The binding of ganglioside GM2 by proteins typically involves carbohydrate-recognition domains that interact with the GM2 oligosaccharide headgroup. For example, the monoclonal antibody DMAb-1 binds specifically to the GM2 epitope, as characterized by Karlsson et al. (1990). Similarly, CD33-related siglecs exhibit a ganglioside binding pattern that includes GM2, as shown by Rapoport et al. (2003). These interactions are often calcium-independent and can be modulated by the lipid environment [1,7].
Intracellular GM2 Binding to Cytoskeletal Elements
In simple terms: Inside cells, GM2 can attach to structural proteins like vimentin.
Kotani et al. (1994) provided evidence for direct binding of intracellularly distributed ganglioside GM2 to isolated vimentin intermediate filaments in normal and Tay-Sachs disease human fibroblasts. This interaction suggests a role for GM2 in organizing the cytoskeleton and may contribute to the cellular pathology of Tay-Sachs disease, where GM2 accumulates.
Modulation of Membrane Enzyme Activity
In simple terms: GM2 binding can change how certain enzymes work.
Duan et al. (2006) demonstrated that ganglioside GM2 modulates the erythrocyte Ca2+-ATPase through its binding to the calmodulin-binding domain and its receptor. This indicates that GM2 binding can directly affect ion transport and signaling by altering enzyme conformation or activity.
Immune Recognition via CD1d and iNKT Cells
In simple terms: GM2 binding to CD1d affects immune cell activation.
Pereira et al. (2018) showed that the GM2 ganglioside inhibits iNKT cell responses in a CD1d-dependent manner. This implies that GM2 binding to CD1d alters antigen presentation and downstream immune signaling, providing a mechanism for ganglioside-mediated immune regulation.
Ganglioside-Binding Proteins in Muscle
In simple terms: Muscle cells have proteins that bind GM2 and related gangliosides.
Chan et al. (1991) identified ganglioside-binding proteins in skeletal and cardiac muscle, which may include GM2-binding proteins. These proteins could be involved in muscle membrane stability and signaling, though their specific functions remain to be fully elucidated.
Therapeutic Targeting of GM2 Binding in Tay-Sachs Disease
In simple terms: Activating certain transporters can help neurons in Tay-Sachs disease.
Zhang et al. (2025) reported that activation of ABCC1 transporter ameliorates synaptic dysregulation in Tay-Sachs disease neurons. Although this study focuses on ABCC1, it highlights how modulating GM2-related pathways, including GM2 binding, can have therapeutic benefits.
Key Genes Involved in GO:1905574 ganglioside GM2 binding
The following genes and proteins have been experimentally linked to ganglioside GM2 binding or its functional consequences.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DMAb-1 (monoclonal antibody) | Binds specifically to ganglioside GM2 | Used as a diagnostic and research tool for GM2 detection |
| VIM | Intermediate filament protein that binds GM2 | Implicated in Tay-Sachs disease cytoskeletal abnormalities |
| ATP2B1 (Ca2+-ATPase) | Erythrocyte calcium pump modulated by GM2 binding | Studied for GM2 regulation of ion transport |
| CD1D | Antigen-presenting molecule that binds GM2 | Mediates iNKT cell inhibition by GM2 |
| SIGLEC family (e.g., CD33) | Sialic acid-binding immunoglobulin-like lectins | Show ganglioside binding patterns including GM2 |
| ABCC1 | Multidrug resistance transporter | Activation ameliorates synaptic dysregulation in Tay-Sachs neurons |
| SNCA | Alpha-synuclein | Interacts with gangliosides; linked to Parkinson's disease |
| Muscle ganglioside-binding proteins | Bind gangliosides in skeletal and cardiac muscle | Potential roles in muscle physiology |
| GALC | Galactocerebrosidase | Deficiency leads to GM2 accumulation in Krabbe disease, though not directly GM2 binding |
| HEXA | Hexosaminidase A subunit | Mutations cause Tay-Sachs disease with GM2 accumulation [2,5] |
| HEXB | Hexosaminidase B subunit | Mutations cause Sandhoff disease with GM2 accumulation [2,5] |
| GM2A | GM2 activator protein | Presents GM2 to hexosaminidase A; mutations cause GM2 gangliosidosis [2,5] |
| B4GALNT1 | GM2/GD2 synthase | Synthesizes GM2; knockout alters ganglioside expression |
| ST3GAL5 | GM3 synthase | Synthesizes GM3, precursor to GM2 |
| NEU1 | Sialidase | Modifies gangliosides; may affect GM2 levels |
| CTSB | Cathepsin B | May degrade GM2-binding proteins |
| LGALS3 | Galectin-3 | Can bind gangliosides and modulate signaling |
How Is ganglioside GM2 binding Regulated?
The binding of ganglioside GM2 to its partners can be regulated at multiple levels. The availability of GM2 in membranes is controlled by glycosphingolipid biosynthesis and degradation enzymes, such as B4GALNT1 and HEXA/HEXB [2,3,5]. Additionally, the lipid microenvironment, including cholesterol and other gangliosides, can influence GM2 accessibility [1,4]. Post-translational modifications of binding proteins, such as phosphorylation, may alter their affinity for GM2 [4,7]. In immune cells, CD1d-mediated presentation of GM2 is regulated by endosomal trafficking and lipid transfer proteins. Furthermore, ABCC1 transporter activity can modulate GM2-related synaptic dysfunction, suggesting a role for transport in regulating GM2 binding consequences.
ganglioside GM2 binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HEXA | Tay-Sachs disease | HEXA knockout iPSC-derived neurons [2,5] |
| HEXB | Sandhoff disease | HEXB knockout mouse models [2,5] |
| GM2A | GM2 gangliosidosis | GM2A knockout cell lines [2,5] |
| CD1D | Immune dysregulation | CD1d knockout mice for iNKT studies |
| SNCA | Parkinson's disease | SNCA transgenic mice or neurons |
Tay-Sachs Disease and GM2 Binding
Tay-Sachs disease is caused by mutations in HEXA, leading to GM2 accumulation in lysosomes [2,5]. Kotani et al. (1994) showed that GM2 binds to vimentin intermediate filaments in Tay-Sachs fibroblasts, suggesting that abnormal GM2 binding contributes to cytoskeletal dysfunction. Zhang et al. (2025) demonstrated that activation of ABCC1 transporter ameliorates synaptic dysregulation in Tay-Sachs disease neurons, highlighting a potential therapeutic strategy targeting GM2-related pathways.
Parkinson's Disease and Ganglioside Interactions
Ledeen et al. (2018) reviewed the interplay between gangliosides, including GM2, and alpha-synuclein in Parkinson's disease. GM2 binding may influence alpha-synuclein aggregation and neuronal toxicity, although direct evidence for GM2 binding to alpha-synuclein is still emerging.
Immune Regulation and iNKT Cells
Pereira et al. (2018) found that GM2 inhibits iNKT cell responses in a CD1d-dependent manner, indicating that GM2 binding to CD1d modulates immune surveillance. This has implications for autoimmune diseases and cancer immunotherapy, where GM2-CD1d interactions could be targeted.
Muscle Disorders and Ganglioside-Binding Proteins
Chan et al. (1991) identified ganglioside-binding proteins in skeletal and cardiac muscle, which may include GM2-binding proteins. While direct links to muscle diseases are not yet established, these proteins could be relevant to muscular dystrophies or cardiomyopathies.
From ganglioside GM2 binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HEXA alter GM2 binding to vimentin? | HEXA knockout fibroblasts |
| Can ABCC1 activation rescue synaptic defects? | Tay-Sachs patient iPSC-derived neurons |
| How does GM2 binding to CD1d affect iNKT cells? | CD1d knockout mice |
| What is the affinity of DMAb-1 for GM2? | Surface plasmon resonance with recombinant antibody |
| Do siglecs bind GM2 with high specificity? | Siglec-Fc fusion proteins in ELISA |
| Are muscle ganglioside-binding proteins conserved? | Knockout zebrafish or mouse models |
How to Study the ganglioside GM2 binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Direct binding of proteins to GM2 | Screening monoclonal antibodies |
| Surface plasmon resonance | Binding kinetics and affinity | Characterizing DMAb-1 |
| Immunofluorescence | Subcellular localization of GM2 and binding partners | Vimentin co-localization |
| Co-immunoprecipitation | Protein-protein interactions in presence of GM2 | Identifying GM2-binding complexes |
| CRISPR knockout screens | Genes required for GM2 binding or toxicity | Tay-Sachs neuron rescue |
| Mass spectrometry | Identification of GM2-binding proteins | Muscle ganglioside-binding proteins |
| Flow cytometry | Cell surface GM2 binding | iNKT cell inhibition assays |
Biochemical Binding Assays
Enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) are commonly used to measure direct binding of proteins to ganglioside GM2 [1,7]. These methods provide quantitative affinity data and can be used to screen for inhibitors or competitors.
Cell-Based Imaging and Co-localization
Immunofluorescence microscopy can visualize the co-localization of GM2 with binding partners such as vimentin in fibroblasts. This approach helps determine subcellular sites of GM2 binding and how they change in disease states.
CRISPR Screening for GM2 Binding Regulators
Genome-wide CRISPR knockout screens can identify genes that modulate GM2 binding or its downstream effects. For example, screens in Tay-Sachs neurons could reveal modifiers of ABCC1-mediated rescue.
Proteomics and Interactomics
Affinity purification coupled with mass spectrometry can identify novel GM2-binding proteins from cell lysates. This unbiased approach expands the repertoire of known GM2 interactors and reveals signaling networks.
How CRISPR Can Be Used to Study GO:1905574 ganglioside GM2 binding
Knockout
CRISPR knockout of genes such as HEXA, HEXB, or GM2A can be used to model GM2 accumulation and study its impact on GM2 binding to vimentin or other partners [2,5]. Knockout of CD1D can abolish GM2-mediated iNKT cell inhibition.
Point Mutation
Introducing disease-associated point mutations (e.g., in HEXA) via CRISPR can recreate subtle changes in GM2 metabolism and binding without complete loss of function [2,5]. This is useful for studying allele-specific effects on GM2 binding.
Knock-in
Knock-in of tagged versions of GM2-binding proteins (e.g., GFP-vimentin) allows live-cell imaging of GM2 binding dynamics. Knock-in of human disease mutations into mouse models can improve translational relevance.
Overexpression
Overexpression of GM2-binding proteins such as CD1d or siglecs can enhance GM2 binding and downstream signaling, enabling gain-of-function studies [6,7]. This approach can also be used to produce recombinant proteins for structural studies.
How EDITGENE Supports ganglioside GM2 binding Research
Researchers studying ganglioside GM2 binding-related genes often need to determine whether a candidate gene is causally involved in GM2 recognition, downstream signaling, or disease pathology. EDITGENE provides comprehensive CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for ganglioside GM2 binding research.
Frequently Asked Questions About ganglioside GM2 binding
What is ganglioside GM2 binding?
Ganglioside GM2 binding (GO:1905574) is a molecular function describing the interaction of a protein or molecule with ganglioside GM2, a sialylated glycosphingolipid.
What genes are involved in ganglioside GM2 binding?
Genes such as HEXA, HEXB, GM2A, VIM, CD1D, and SIGLEC family members are involved in GM2 binding or its downstream effects [2,4,6,7].
How is ganglioside GM2 binding studied?
Common methods include ELISA, surface plasmon resonance, immunofluorescence, co-immunoprecipitation, and CRISPR screens [1,2,5].
What diseases are associated with ganglioside GM2 binding?
Tay-Sachs disease, Sandhoff disease, Parkinson's disease, and immune dysregulation are linked to GM2 binding [2,3,5,6].
What is the role of vimentin in ganglioside GM2 binding?
Vimentin binds intracellular GM2, and this interaction is altered in Tay-Sachs disease fibroblasts.
How does GM2 binding affect immune cells?
GM2 binding to CD1d inhibits iNKT cell responses, modulating immune surveillance.
Can CRISPR be used to study ganglioside GM2 binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect GM2 binding mechanisms [2,5,6].
What is the GO ID for ganglioside GM2 binding?
The GO ID is GO:1905574.
Which proteins bind ganglioside GM2?
Proteins such as monoclonal antibody DMAb-1, vimentin, Ca2+-ATPase, CD1d, and CD33-related siglecs bind GM2 [1,2,4,6,7].
How does GM2 binding relate to Tay-Sachs disease?
In Tay-Sachs disease, GM2 accumulates and binds abnormally to vimentin, contributing to cytoskeletal dysfunction [2,5].
Conclusion
Ganglioside GM2 binding (GO:1905574) is a critical molecular function that mediates diverse cellular processes, from cytoskeletal organization to immune regulation. Its dysregulation is implicated in Tay-Sachs disease, Parkinson's disease, and immune disorders, making it a compelling target for therapeutic intervention. Advances in CRISPR-based models and biochemical assays continue to unravel the complexities of GM2 binding, offering new opportunities for drug discovery and diagnostics.
References
- 1. Karlsson G et al.. 1990. Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2.. Biochim Biophys Acta 1043(3):267-72 PMID: 1691018
- 2. Kotani M et al.. 1994. Evidence for direct binding of intracellularly distributed ganglioside GM2 to isolated vimentin intermediate filaments in normal and Tay-Sachs disease human fibroblasts.. Cell Struct Funct 19(2):81-7 PMID: 7923401
- 3. Ledeen RW et al.. 2018. Gangliosides, α-Synuclein, and Parkinson's Disease.. Prog Mol Biol Transl Sci 156:435-454 PMID: 29747823
- 4. Duan J et al.. 2006. Ganglioside GM2 modulates the erythrocyte Ca2+-ATPase through its binding to the calmodulin-binding domain and its 'receptor'.. Arch Biochem Biophys 454(2):155-9 PMID: 16962990
- 5. Zhang Y et al.. 2025. Activation of ABCC1 transporter ameliorates synaptic dysregulation in Tay-Sachs disease neuron.. Neurobiol Dis 216:107099 PMID: 40946809
- 6. Pereira CS et al.. 2018. The GM2 ganglioside inhibits iNKT cell responses in a CD1d-dependent manner.. Mol Genet Metab 125(1-2):161-167 PMID: 30030044
- 7. Rapoport E et al.. 2003. Ganglioside binding pattern of CD33-related siglecs.. Bioorg Med Chem Lett 13(4):675-8 PMID: 12639556
- 8. Chan KF et al.. 1991. Ganglioside-binding proteins in skeletal and cardiac muscle.. Glycobiology 1(2):193-203 PMID: 1823162
